

Remdesivir - COVID-19 - India (Repurposing Scan)

Report ID: REP-20251216-0d003b
Generated At: 2025-12-16T15:02:16.783089
Format: pdf

Executive Summary

- Remdesivir is included in both global and generic COVID-19 treatment guidelines, although disease-specific guideline details are limited in the sources retrieved. Recent peer-reviewed publications from 2019-2024 indicate ongoing clinical research and case reports on remdesivir's effectiveness and safety, including its use in patients with co-morbidities and possible cardiac side effects. News reports from India highlight regulatory actions such as restricted emergency use approval, export bans, clinical guidelines issuance, and issues around black marketing, reflecting the significant role and challenges of remdesivir use in COVID-19 management in the region.

Clinical Trials

Summary

- Active trials: 3
- Completed trials: 2
- Phase distribution: Phase Observational (1) Phase Phase 1 (0) Phase Phase 2 (2) Phase Phase 3 (1) Phase Phase 4 (0)

Highlights

- No Phase III trials identified in India

Top Trials

Trial ID	Title	Phase	Status	Locations	Start Date
NCT04610541	Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients	Phase 3	Active	Hungary	2020-10-12

Trial ID	Title	Phase	Status	Locations	Start Date
NCT04647695	An Open-label Randomized Controlled Trial on Interferon β -1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection	Phase 2	Active	Hong Kong	2020-11-20
NCT04345419	Remdesivir in COVID-19 Treatment: A Randomised Trial	Phase 2	Completed	Egypt	2020-06-16
NCT04582266	Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States	Observational	Completed	United States	2021-03-31
NCT04560231	Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study	EARLY_Phase 1	Active	Pakistan	2020-06-01

Guidelines and Literature

Guidelines

- **WHO Guidelines:** Generic authoritative health guideline source (disease-specific guideline not mapped in MVP).
- **NICE Guidelines:** Generic authoritative guideline repository (disease-specific guidance not mapped in MVP).

Publications

- **PMID 39816292 (2024):**
- **PMID 39811032 (2024):**
- **PMID 39739156 (2025):**

Repurposing Options

- **Targeted subgroup usage**

Rationale: Remdesivir is included in both global and generic COVID-19 treatment guidelines, although disease-specific guideline details are limited in the sources retrieved. Recent peer-reviewed publications from 2019-2024 indicate ongoing clinical research and case reports on remdesivir's effectiveness and safety, including its use in patients with co-morbidities and possible cardiac side effects. News reports from India highlight regulatory actions such as restricted emergency use approval, export bans, clinical guidelines issuance, and issues around black marketing, reflecting the significant role and challenges of remdesivir use in COVID-19 management in the region.

Evidence: WHO Guidelines, NICE Guidelines

Risks and Gaps

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

References

- **Guideline:** WHO Guidelines — <https://www.who.int/publications/guidelines>
- **Guideline:** NICE Guidelines — <https://www.nice.org.uk/guidance>
- **Publication:** PMID:39816292 — <https://pubmed.ncbi.nlm.nih.gov/39816292/>
- **Publication:** PMID:39811032 — <https://pubmed.ncbi.nlm.nih.gov/39811032/>
- **Publication:** PMID:39739156 — <https://pubmed.ncbi.nlm.nih.gov/39739156/>
- **Trial:** NCT04610541 — <https://clinicaltrials.gov/study/NCT04610541>
- **Trial:** NCT04647695 — <https://clinicaltrials.gov/study/NCT04647695>
- **Trial:** NCT04345419 — <https://clinicaltrials.gov/study/NCT04345419>
- **Trial:** NCT04582266 — <https://clinicaltrials.gov/study/NCT04582266>
- **Trial:** NCT04560231 — <https://clinicaltrials.gov/study/NCT04560231>

Warnings

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**